In 2005 a tender to buy medicines against AIDS and sexually transmitted diseases for $ 10,095,492, the Ministry of Health paid 23.5% more than the reference price indicated.

A report from the General Audit Office (AGN, for its acronym in Spanish), notes that spending increased because the portfolio called remedies "without the notice required" to meet demand in the first half of that year. The request was issued on May 30 and compliance with the provisions was conducted between December and January 2006. In addition, the stock of the products was "critical" and "several lines of the tender were awarded to higher prices." In such cases, there is a resolution of the Office of the Comptroller (SIGEN), the 79/2005, which establishes a mandatory mechanism to improve prices and "align with market values", but according to the AGN, Health did not establish that they used that tool.

Also, the work of the Watchdog detected that direct contracting of the portfolio, also of AIDS drugs, "there was no evidence of obtained price estimates as a reference value, nor was the amount of the finally awarded justified" about $ 5,238,291.

To "avoid potential problems of stock", the Ministry had hired directly providing medical drugs for $ 575,971. However, the audit found "extensive delay" in carrying out this operation, because the purchase order was dated May 3rd and the products were received on October 28.

The AGN found other irregularities in procurement portfolio. In public bidding 11/05, for example, it was found that "the company Roche did not submit the proof of registration in the Supplier Information System or a certificate for hire (AFIP)", however, the company managed to sentence 13 of the the tender for $ 7,026,402.

In the audit, the Ministry bought products Elea, Richmond and Filaxis laboratories, according to a report by the ANMAT "they did not fill out the bioavailability and bioequivalence requirements" required by the Ministry of Health and Foreign Policy.

Meanwhile, Health has revolving funds, which are items for expenditure to be expressly authorized. In 2005, these funds amounted to $ 1,160,676 and the Audit noted that 74% of this total was used in the purchase of drugs "rather than substantiate the contractual formalities in accordance with current standards."